Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium (99mTc) trofolastat
- Development stage
- Unknown
- Lead developer
- Lantheus
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Technetium (99mTc) trofolastat (99mTc-MIP-1404) is a small-molecule radiopharmaceutical diagnostic imaging agent designed for the detection and staging of prostate cancer using SPECT/CT. It consists of a glutamate-urea-lysine binding motif that targets the extracellular enzymatic domain of Prostate-Specific Membrane Antigen (PSMA), which is highly overexpressed in approximately 95% of prostate cancer cells. The molecule utilizes proprietary Single Amino Acid Chelate (SAAC) technology to bind the technetium-99m radioisotope. Following intravenous administration, the tracer selectively concentrates in PSMA-positive primary and metastatic prostate cancer lesions, allowing for high-contrast visualization 3–6 hours post-injection. It has been evaluated in Phase 3 clinical trials for the detection of prostate cancer in men with high-risk disease scheduled for prostatectomy and for the localization of recurrence in patients with biochemical failure.
- Other names
- Technetium Tc 99m trofolastat99mTc-labeled PSMA inhibitor
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on technetium (99mTc) trofolastat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium (99mTc) trofolastat.